It feels slightly surreal to be writing about this year’s annual ESMO confab instead of attending in person in Madrid, Spain.
While much of the time and attention at ESMO is usually focused on the major phase 3 readouts from various clinical trials, we will be covering these during the meeting as they are presented to avoid repetition since many of the topline company trial results have already been announced.
In this year’s conference Preview series, I wanted to take a step back and explore early new product development in several forms:
- Biomarkers and potential new ways of predicting outcomes in development
- Emerging novel targets of interest
- Developmental therapeutics – trials and tribulations
This initial review will tackle some important developments pertaining to various biomarkers of interest.